Evaluation of Human MSCs Treatment Frequency on Airway Inflammation in a Mouse Model of Acute Asthma
Hur Jung, 강지영, 김영균, 이숙영, Jeon So-Ra, Kim You-Rha, 정찬권, 이진국,
소속 상세정보
( Hur Jung ) - Catholic University College of Medicine Seoul St. Mary’s Hospital Department of Internal Medicine
강지영 ( Kang Ji-Young ) - Catholic University College of Medicine Seoul St. Mary’s Hospital Department of Internal Medicine
김영균 ( Kim Young-Kyoon ) - Catholic University College of Medicine Seoul St. Mary’s Hospital Department of Internal Medicine
이숙영 ( Lee Sook-Young ) - Catholic University College of Medicine Seoul St. Mary’s Hospital Department of Internal Medicine
( Jeon So-Ra ) - Catholic University College of Medicine Seoul St. Mary’s Hospital Department of Hospital Pathology
( Kim You-Rha ) - Catholic University College of Medicine Seoul St. Mary’s Hospital Department of Hospital Pathology
정찬권 ( Jung Chan-Kwon ) - Catholic University College of Medicine Seoul St. Mary’s Hospital Department of Hospital Pathology
이진국 ( Rhee Chin-Kook ) - Catholic University College of Medicine Seoul St. Mary’s Hospital Department of Internal Medicine
Abstract
Background: Studies in experimental models of allergic asthma have shown that mesenchymal stem cells (MSCs) have therapeutic potential for T-helper 2 (TH2) cell-mediated inflammation. However, the mechanisms underlying these therapeutic effects are not fully understood and their safety has not been confirmed.
Methods: Using a mouse model of experimental allergic asthma, we investigated the efficacy of human adipose-derived mesenchymal stem cells (hADSCs) or human bone marrow-derived mesenchymal stem cells (hBMSCs) according to treatment frequency and timing.
Results: Ovalbumin (OVA)-sensitized and -challenged mice exhibited airway hyperresponsiveness (AHR), airway inflammation, and significant increases in TH2 cytokine levels. Both double and single human mesenchymal stem cell (hMSC) treatments significantly decreased AHR and bronchoalveolar lavage fluid counts. In addition, single treatment with hMSCs showed significant attenuation of allergic airway inflammation. However, double treatment with hMSCs during OVA -sensitization and -challenge further increased inflammatory cell infiltration, and TH2 cytokine levels.
Conclusion: The results of treatment with hADSCs or hBMSCs suppresses AHR and airway inflammation. However, double hMSC treatment significantly induces eosinophilic airway inflammation and lung histological changes. Therefore, double hMSC treatment is ineffective against asthma and single injection frequency appears to be more important for the treatment of asthma. These results suggest that hMSC therapy can be used for treatment of asthma patients but that it should be used carefully.
키워드
Human MSC; Frequency; Airway Inflammation; Asthma
원문 및 링크아웃 정보
등재저널 정보